Attendee search 

Canbex is dedicated to improving the quality of life for people with multiple sclerosis (MS) and potentially other disorders, through better treatment for spasticity. 

Spasticity is the sudden and uncontrollable movement of limbs and torso, and is among the most painful, damaging and debilitating symptoms of MS.  Current drug treatments for spasticity are effective but are plagued by sedative and other side effects that sharply limit their usefulness.

Canbex closed a $3.2m financing round led by Merck Serono Ventures in April 2013, and its lead anti-spasticity compound, VSN16R, is set to enter Phase I safety testing.  In studies to date, VSN16R shows substantially improved tolerability compared to other compounds, and is as effective against spasticity as any other agent known.

Supported by its leading London-based scientific and clinical team, Canbex believes that VSN16R has the potential to meet an important medical need, and to address a highly attractive commercial opportunity. 

To find out more, please meet us at the event or contact us using the details below

Canbex Therapeutics Ltd

London BioScience Innovation Centre

2 Royal College Street

London

NW1 0NH

Tel: +44 (0)207 554 5872

Email: enquiries@canbex.co.uk

Bristows is a law firm dedicated to serving businesses with interests in intellectual property and technology, in industry sectors ranging from pharmaceuticals, electronics,IT and telecommunications to consumer products, television and entertainment.

The company develops companion diagnostic tests and biomarker discovery platforms based on its unique analytical technology, the CycloChipTM. The tests come in the form of disposable cartridges specific to desired applications. 

Direct comparative studies, have shown that the technology is between 30x-270x times faster, with over 10x higher resolution and 2000x more sensitive than competing top of the range analytical instruments.

The fact that this performance can be achieved in disposable devices that can be flexibly customised to different diagnostic and analytical applications, makes this device very attractive diagnostic companies and CROs.

GMD is looking for end-users of the technology to tailor the disposable cartridges to their specific needs. 

The CycloChipTM performs the tests based on a unique molecular separation method that allows for unprecedented throughput, sensitivity and resolution. Unlike chemistry based diagnostic companions, our system is not limited to a single molecule or a small number of molecules, but rather it can be tailored to an endless number of different molecular tests, tailored to the needs of our pharmaceutical or diagnostic client.

The GMD system can be applied to both proteomic and genomic analyses.

GMD is looking for a partner/end user to out license its technology and at the same time develop its product portfolio driven by the specific needs of the end-user. The latter could be a pharmaceutical company with internal R&D or a diagnostic company. 

GMD is based at Kingston University, London. It's technology has been awarded multiple prestigeous grants, from the London Development Agency and Technology Strategy Board.

Glythera is an emerging biotechnology company specializing in the development of next generation biotherapeutics through the application of its advanced proprietary conjugation and glycosylation technologies.

Located in the North East of the UK with its dedicated bioprocessing and chemistry development laboratories at Newcastle University, Glythera is positioned as a critical partner in any development program centred on its PermaLink™ and PermaCarb™ technologies.

Our PermaLink™ platform supports highly selective site specific conjugation whilst demonstrating significantly increased stability with our core focus being in the development of enhanced Antibody Drug Conjugates and bi-specifics.

Glythera’s PermaCarb™ technology allows direct substitution of endogenous glycan’s or correction of micro-heterogeneity using stable analogues to improve bioavailability and efficacy and has been demonstrated in a range of next generation biotherapeutics.

Our Mission is to enable improved clinical regimes through the creation of the next generation of safe, efficacious biotherapeutic products in oncology and therapeutic indications.

MGB Biopharma is a private company based in Glasgow, Scotland and is backed by a syndicate of Scotland’s leading angel investor groups together with Scottish Enterprise.

Antimicrobial drug resistance is recognised as a global public health concern with an urgent need for new antibacterial drug classes that are more effective than existing treatments. MGB is developing the first truly novel class of anti-infectives in over a decade that has the potential to treat infections of a number of the most important susceptible and resistant pathogens. Our lead compound has shown strong bactericidal activity with quick onset of action against many strains of Gram-positive bacteria. It has completed pre-clinical development and progress into our phase 1 clinical study for the treatment of Clostridium difficile have been endorsed by the MHRA. Optimisation of a new formulation for intravenous administration and treatment of systemic Gram-positive infection is ongoing.

MGB has acquired exclusive rights to the proprietary minor groove binder platform, developed at the University of Strathclyde, Glasgow. This platform provides an opportunity to develop additional compounds with the potential to treat Gram-negative, viral, fungal and parasitic infections.

MGB continues to work closely with Strathclyde University to develop the pipeline and is currently seeking partners to help maximise the value-creating opportunities from its broad platform.

BioPartner is your UK point of contact at Bio-Europe 2013 based at stand #68.

BioPartner is an independent, accredited trade organisation, promoting international partnering for trade, investment and collaborations with UK Life Science companies. Through the BioPartnership Programme, BioPartner assists companies to attend major international biopharma conferences by providing access to government grants and heavily discounted entry fees.